Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:10
  • preuzimanja u poslednjih 30 dana:1
članak: 4 od 134  
Back povratak na rezultate
Acta medica Medianae
2018, vol. 57, br. 3, str. 48-54
jezik rada: engleski
vrsta rada: originalan članak
doi:10.5633/amm.2018.0306

Creative Commons License 4.0
Ekspresija epigenetskog prigušivača EZH2 u rano invazivnom PT1 urotelnom karcinomu mokraćne bešike
aUniverzitet u Nišu, Medicinski fakultet
bKlinka Elbe-Elster, Herzberg, Nemačka
cUniverzitet u Nišu, Medicinski fakultet + Centar za patologiju, Klinički centar Niš, Niš
dKlinika za onkologiju, Klinički centar Niš, Niš

e-adresa: slavica.stojnev@medfak.ni.ac.rs

Projekat

Etiologija, dijagnostika, prevencija, i terapija endemske nefropatije i sa njom povezanih tumora urotela - značaj istraživanja genoma i proteoma (MPNTR - 175092)

Sažetak

Urotelni karcinom mokraćne bešike je najčešća maligna neoplazma urinarnog trakta. Rano invazivni karcinom bešike (stadijum pT1) je tumor u kojem je prisutna invazija subepitelnog vezivnog tkiva, bez zahvatanja mišićnog sloja. Predstavlja veliki izazov za dijagnozu i lečenje. EZH2 transkripcioni represor igra ključnu ulogu u onkogenezi mokraćne bešike. Cilj ovog istraživanja bio je da ispita profil ekspresije EZH2 u pT1 karcinomu bešike, analizira korelaciju ekspresije EZH2 sa kliničko-patološkim faktorima i da proceni njen prognostički značaj. U tom cilju je imunohistohemijski analizirano 279 tumora ukalupljenih u tkivne mikroareje na ekspresiju EZH2. Visoka jedarna ekspresija EZH2 zabeležena je u 44,5% tumora. Visoka EZH2 ekspresija bila je udružena sa visokim histološkim gradusom (p < 0,001). Pored toga, EZH2 značajno je korelirao sa muškim polom i pojavom karcinoma in situ u okolnom urotelu (p = 0,019 i p = 0,026), dok divergentna diferencijacija tumora i pojava recidiva bolesti nisu pokazale značajnu udruženost sa ekspresijom EZH2. Visoka EZH2 ekspresija bila je snažno povezana sa specifičnim mortalitetom uzrokovanim karcinomom (p = 0,010). Kaplan-Majer analiza preživljavanja pokazala je da visoka ekspresija EZH2 predviđa lošije preživljavanje obolelih (p < 0,001). Uticaj EZH2 na vreme bez razvoja relapsa tumora nije se pokazao statistički značajnim. Visoka ekspresija EZH2 u rano invazivnom karcinomu mokraćne bešike ukazuje na agresivno ponašanje tumora i lošiju prognozu. EZH2 ima potencijalno značajne uloge kao komplementarno sredstvo u dijagnostici za selekciju bolesnika koji zahtevaju intenzivniju pažnju kliničara i kao potencijalna meta antikancerogene terapije.

Ključne reči

urotelni karcinom bešike; EZH2; imunohistohemija; prognoza

Reference

Bertz, S., Otto, W., Denzinger, S., Wieland, W.F., Burger, M., Stöhr, R., Link, S., Hofstädter, F., Hartmann, A. (2014) Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer. European Urology, 65(1): 218-226
Burger, M., Catto, J.W.F., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeney, L.A., La, V.C., Shariat, S., Lotan, Y. (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 63(2): 234-241
Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507(7492): 315-322
Cao, Q., Yu, J., Dhanasekaran, S.M., Kim, J.H., Mani, R., Tomlins, S.A., Mehra, R., Laxman, B., Cao, X., Yu, J., Kleer, C.G., Varambally, S., Chinnaiyan, A.M. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 27(58): 7274-7284
Casadevall, D., Kilian, A.Y., Bellmunt, J. (2017) The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. Cancer Treatment Reviews, 61: 82-93
Chase, A., Cross, N.C.P. (2011) Aberrations of EZH2 in Cancer. Clinical Cancer Research, 17(9): 2613-2618
Ding, X., Yang, X., Liang, G., Wang, K. (2016) Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2′-deoxycytidine. Scientific Reports, 6(1):
Kitamura, H., Kakehi, Y. (2015) Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?. Japanese Journal of Clinical Oncology, 45(4): 315-322
Liu, D., Li, Y., Luo, G., Xiao, X., Tao, D., Wu, X., Wang, M., Huang, C., Wang, L., Zeng, F., Jiang, G. (2017) LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Letters, 388: 281-291
Lopez-Beltran, A., Cheng, L. (2003) Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology, 35(6): 484-491
Luo, M., Li, Z., Wang, W., Zeng, Y., Liu, Z., Qiu, J. (2013) Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Letters, 333(2): 213-221
Martínez-Fernández, M., Rubio, C., Segovia, C., López-Calderón, F., Dueñas, M., Paramio, J. (2015) EZH2 in Bladder Cancer, a Promising Therapeutic Target. International Journal of Molecular Sciences, 16(11): 27107-27132
Morera, L., Lübbert, M., Jung, M. (2016) Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clinical Epigenetics, 8(1):
Patriarca, C., Hurle, R., Moschini, M., Freschi, M., Colombo, P., Colecchia, M., Ferrari, L., Guazzoni, G., Conti, A., Conti, G., Lucianò, R., Magnani, T., Colombo, R. (2016) Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagnostic Pathology, 11(1):
Raman, J.D., Mongan, N.P., Tickoo, S.K., Boorjian, S.A., Scherr, D.S., Gudas, L.J. (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res, 11(24 Pt 1): 8570-6
Santos, M., Martinez-Fernandez, M., Duenas, M., Garcia-Escudero, R., Alfaya, B., Villacampa, F., Saiz-Ladera, C., Costa, C., Oteo, M., Duarte, J., Martinez, V., Gomez-Rodriguez, M.J., Martin, M.L., Fernandez, M., Viatour, P., Morcillo, M.A., Sage, J. (2014) In Vivo Disruption of an Rb-E2F-Ezh2 Signaling Loop Causes Bladder Cancer. Cancer Research, 74(22): 6565-6577
Segovia, C., Martínez-Fernández, M., Dueñas, M., Rubio, C., López-Calderón, F.F., Costa, C., Saiz-Ladera, C., Fernández-Grajera, M., Duarte, J., Muñoz, H.G., de la Rosa, F., Villacampa, F. (2017) Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget, 8(6):
Takawa, M., Masuda, K., Kunizaki, M., Daigo, Y., Takagi, K., Iwai, Y., Cho, H., Toyokawa, G., Yamane, Y., Maejima, K., Field, H.I., Kobayashi, T., Akasu, T., Sugiyama, M., Tsuchiya, E. (2011) Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Science, 102(7): 1298-1305
Wang, H., Albadine, R., Magheli, A., Guzzo, T.J., Ball, M.W., Hinz, S., Schoenberg, M.P., Netto, G.J., Gonzalgo, M.L. (2012) Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 30(4): 428-433
Warrick, J.I., Raman, J.D., Kaag, M., Bruggeman, T., Cates, J., Clark, P., DeGraff, D.J. (2016) Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 34(6): 258.e1-258.e6
Yamaguchi, H., Hung, M. (2014) Regulation and Role of EZH2 in Cancer. Cancer Research and Treatment, 46(3): 209-222